Second malignant tumors in patients with laryngeal carcinoma: Diagnosis, treatment, and prevention

McDonald, Sandra; Haie, C.; Rubin, Philip; Nelson, Diana F.; Divers, Lorrie D.

doi:10.1016/0360-3016(89)90095-3

Cited by 98 publications

(51 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seventeen had a SPT in the lung, while in three cases the lesion was identified by ICC and subsequently clinically and/or pathologically as metastatic from a colon, a breast and a prostate carcinoma. These findings bear particular relevance in melanoma patients who have an increased risk of developing a pulmonary SPT (Perry et al, 1986), and in patients with head and neck cancer, which most frequently metastatize to the lung (Cooper et al, 1989;McDonald et al, 1989). In addition, metastatic melanoma may often be amelanotic, as also evident in our group of patients, thus raising further diagnostic problems.…”

Section: Discussionsupporting

confidence: 59%

Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies

Mottolese¹,

Venturo

Rinaldi

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary The longer survival of neoplastic patients achieved through improvements of therapeutic regimens has increased the relative risk of developing a second primary tumour (SPT). In this context, conventional cytopathology can define tumour histotype only in a small fraction of cases. In this study, we have evaluated whether selected combinations of monoclonal antibodies (MAbs) to tumour-associated antigens (TAAs) al, 1986;Tucker et al, 1988) and solid tumours (Lee, 1986;Kaldor et al, 1987). As early diagnosis of SPTs has major therapeutic and epidemiological relevance (Kaldor et al, 1987;Giardini et al, 1993), the development of new methods for the accurate detection of second malignancies should be attempted. In this context, exfoliative and FNA cytology may be considered a valuable and accurate diagnostic technique, easy to perform on a large scale during the follow-up of patients previously treated for malignant tumours. These methods also have the advantage of minimal morbidity and low cost (Koss, 1988). While this approach has been reported to be highly accurate in identifying metastatic cells, the possibility of defining the tumour histotype has been far less successful (Friedman et al, 1983;Hajdu et al, 1984). We have previously reported that the use of selected combinations of MAbs to TAAs can be applied to a number of areas of cytodiagnosis of solid tumours, thus increasing the accuracy of conventional morphology in identifying metastases from unknown primary tumour and in differentiating primary from metastatic lesions (Mottolese et al, 1993). In the present study, we have analysed, in a large group of patients with a past history of malignancy, whether the use of a similar panel of reagents may also be useful in detecting SPTs in two areas of cytopathology, which are particularly difficult on the basis of morphological criteria, namely that of effusions and of pulmonary FNA. MATERIALS AND METHODS PatientsFrom January 1990 to June 1995, 334 cytological specimens, of which 91 were pulmonary FNA and 243 pleural and peritoneal effusions sampled from patients previously treated with chemo and/or radiotherapy for different malignant tumours, were analysed both cytologically and immunocytochemically (ICC). The series consisted of 93 patients with effusions and 52 with solitary or multiple pulmonary masses, which appeared within 5 years of a previous tumour, while 189 patients developed effusions (150 cases) or radiologically assessed lung lesions (39 cases) at least 5 years after the first tumour. Only those cases in which morphological examination assessed the presence of malignant cells on cytological specimens have been included in this study. Unsatisfactory or insufficient specimens were excluded. Preparation of cell substratesPleural and peritoneal effusions were collected in sterile conditions using heparin (Liquemin Roche) as anticoagulant. Samples were centrifuged at 160 g for 10 min and the recovered cells were resuspended, after three washings with Hanks' balanced salt solution (Gibco Labor...

show abstract

Section: Discussionsupporting

confidence: 59%

Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies

Mottolese¹,

Venturo

Rinaldi

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…[32,33] According to the literature, the incidence of second primary malignancy in larynx cancers ranges between 11-29%. [34][35][36] In a populationbased study performed between 1986-2008, Liao et al determined that 9,996 patients out of 93,891 patients with head neck cancer (11%) had second primary malignancies. In this study, the most frequent organ associated with the second primary malignancy was the nasopharynx (39%), whereas this frequency was 14% for the larynx.…”

Section: Discussionmentioning

confidence: 99%

Treatment results, side effects and prognostic factors affecting survival in patients with larynx cancer

Yücel¹

2013

J Med Updates

View full text Add to dashboard Cite

ÖzetAmaç: Bu çal›flmada, klini¤imizde tedavi edilen larinks kanserli hastalar›n tedavi sonuçlar›, tedavilerin yan etkileri ve hastalar›n sa¤kal›-m›n› etkileyen prognostik faktörlerin belirlenmesi amaçlanm›flt›r.Yöntem: Çal›flmada 90 hasta verisi analiz edilmifltir. Hastalar›n performans statüsü 2010'da revize edilmifl Do¤u Onkoloji ‹flbirli¤i Grubu (Eastern Cooperative Oncology Group, ECOG) skorlama sistemine göre de¤erlendirilmifltir. Bulgular:Hastalar›n %97'si erkek ve %3'ü kad›n olup, medyan yafl› 59 (37-86) idi. Erken evre %43, lokal ileri evre %55, metastatik evre kanser %2 hastada saptand›. Hastalar›n %53'ünü glottik kanserler, %47'sini supraglottik kanserler oluflturmaktayd›. Supraglottik kanserlerin performans durumu (p=0.022), grade (p=0.033), T evresi (p=0.034), lenf nod metastaz› (p=0.001), hastal›k evresi (p=0.007) bak›m›ndan glottik kanserlere göre daha kötü özelliklere sahip oldu¤u saptand›. Medyan 15 (da¤›l›m: 5-96) ayda hastalar›n %17'sinde nüks, medyan 17 (da¤›l›m: 1-155) ayda da hastalar›n %12'sinde uzak metastaz tespit edildi. Hastalar›n sa¤kal›m›n› komorbidite (p=0.032), performans durumu (p=0.022), hemoglobin düzeyi (p=0.003), T evresi (p=0.006), hastal›k evresi (p=0.011), kilo kayb› (p=0.002) etkilemekteydi. Kemoradyoterapi uygulanan hastalarda mukozit (p<0.001), bulant› kusma (p<0.001), kilo kayb› (p=0.005), nötropeni (p=0.001) ve anemi (p=0.003), radyoterapi uygulanan hastalara göre daha fazla gözlenmifltir.Sonuç: Hemoglobin düzeyi, T evresi, komorbidite ve kilo kayb› bu hastalar için ba¤›ms›z prognostik faktörler olmufltur.Anahtar sözcükler: Larinks kanseri, sa¤kal›m, prognoz, yan etki. AbstractObjective: Our aim was to determine the treatment results, side effects and the prognostic factors affecting survival in patients with larynx cancer treated in our clinic. Methods:Data of a total of 90 patients with larynx carcinoma were included in the study. The patients' performance scores were evaluated according to the Eastern Cooperative Oncology Group (ECOG) system.Results: Eighty-seven (97%) patients were male and three patients (3%) were female. The median age of the patients was 59 (37-86) years. Early-stage, locally advanced stage, and metastatic disease were detected in 43, 55, and 2% of the patients, respectively. Laryngeal cancers were observed in the glottic (53%), and supraglottic (47%) regions. Performance score (p=0.022), grade (p=0.033), lymph node metastasis (p=0.001), T stage (p=0.034) and disease stage (p=0.007) were significantly unfavourable in supraglottic cancers compared to glottic cancers. Recurrence was observed in 17% of the patients in a median 15 (range: 5-96) months. Distant metastasis was observed in 12% of the patients in a median 17 (range: 1-155) months. The factors affecting survival were the presence of comorbidities (p=0.032), performance status (p=0.022), hemoglobin level (p=0.003), T stage (p=0.006), disease stage (p=0.011), and weight loss (p=0.002). When RT-and CRT-associated side effects were compared, the incidence of adverse effects such as mucositis ...

show abstract

“…A major cause of failure in early-stage patients is the development of second primary tumors (SPTs; Refs. [2][3][4][5][6]. Patients with an index cancer of the upper aerodigestive tract incur a 4 -7% annual risk of developing a potentially fatal SPT (7)(8)(9)(10), and this risk of developing a SPT does not decrease over time (9,11).…”

Section: Introductionmentioning

confidence: 99%

Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck Cancer

Wu¹,

Zhao²,

Anh³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Second primary tumors (SPTs) are a hallmark of head and neck squamous cell carcinomas (HNSCCs). Serum levels of insulin growth factors (IGFs) and their binding proteins (IGFBPs) have been associated with subsequent development of several epithelial cancers in prospective studies.Experimental Design: To examine the role of IGFs in SPT development, we conducted a nested case-control study within a randomized, placebo-controlled chemoprevention trial in patients with early-stage HNSCC. We compared prediagnostic serum IGF-I and IGFBP-3 levels in 80 patients who subsequently developed SPTs and 173 controls (patients without SPTs) matched to the cases on age (؎5 years), sex, ethnicity, year of randomization, and length of follow-up.Results: The cases exhibited significantly higher levels of IGF-I and IGFBP-3 than did the controls (P ‫؍‬ 0.001 and 0.019, respectively). Elevated IGF-I levels were associated with a 3.66-fold significantly increased risk of SPT. Lower and higher IGFBP-3 levels were associated with a 2.22-and 7.12-fold significant increased risk, respectively. The median SPT-free time was significantly shorter in patients with higher IGF-I levels than in patients with lower IGF-I levels (P < 0.0001). A similar trend was observed for IGFBP-3 (P ‫؍‬ 0.002). Moreover, in the Cox proportional hazards model, higher IGF-I levels were significantly associated with increased risk of SPT with a hazard ratio of 2.78. Patients with the lower and higher IGFBP-3 levels also exhibited significantly increased risks with hazard ratios of 1.65 and 2.17, respectively.Conclusions: This is the first study demonstrating that higher IGF-I levels, and lower and higher IGFBP-3 levels are risk factors for SPT development. Thus, measuring serum IGF-I and IGFBP-3 levels may be useful markers in assessing the risk of second tumors in patients successfully treated for their index cancer.

show abstract

Second malignant tumors in patients with laryngeal carcinoma: Diagnosis, treatment, and prevention

Cited by 98 publications

References 31 publications

Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies

Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies

Treatment results, side effects and prognostic factors affecting survival in patients with larynx cancer

Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck Cancer

Contact Info

Product

Resources

About